NCT07145177View on ClinicalTrials.gov

177Lu-PSMA-617 With Liver Directed Therapy in Metastatic Castration Resistant Prostate Cancer

PHASE1Not yet recruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

October 31, 2025

Primary Completion Date

August 31, 2028

Study Completion Date

August 31, 2030

Conditions
Metastatic Prostate CancerProstate Cancer
Interventions
DRUG

177Lu-PSMA-617

Given intravenously (IV)

PROCEDURE

Ablation

Undergo ablation

PROCEDURE

Trans-arterial chemoembolization (TACE)

Undergo TACE

PROCEDURE

Positron Emission Tomography (PET)/Computerized tomography (CT)

Undergo imaging

PROCEDURE

Tumor Biopsy

Undergo biopsy

OTHER

Questionnaire

Participant will complete questionnaire

Trial Locations (1)

94143

University of California, San Francisco, San Francisco

Sponsors

Collaborators (1)

Novartis
All Listed Sponsors
collaborator

Novartis

INDUSTRY

lead

University of California, San Francisco

OTHER

NCT07145177 - 177Lu-PSMA-617 With Liver Directed Therapy in Metastatic Castration Resistant Prostate Cancer | Biotech Hunter | Biotech Hunter